Anaplastic Large Cell Lymphoma - 61 Studies Found

Available : A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001
:
  • Disease, Hodgkin
  • Lymphoma, Large-Cell, Anaplastic
  • Lymphoma
    : 2010-09-03
    : Drug: brentuximab vedotin Every 21 days by intravenous infusion (1.8 mg/kg)
Completed : Combination Chemotherapy in Treating Children With Lymphoma
: Lymphoma
: 1999-11-01
:
  • Biological: filgrastim Other N
Recruiting : A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer
:
  • Non-Small Cell Lung Cancer (ALK-positive)
  • Non-Small Cell Lung Cancer (c-Met Dependent)

    • : 2007-12-29
    :
    • Drug: PF-02341066 Escalating d
Recruiting : Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma
:
  • Adult Nasal Type Extranodal NK/T-cell Lymphoma
  • Anaplastic Large Cell L
    : 2014-09-03
    :
    • Drug: romidepsin Given IV
Terminated : Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma
:
  • Follicular Lymphoma
  • Marginal Zone Lymphoma
  • Mantle Cell Lym
    : 2008-03-24
    : Drug: Clofarabine Taken orally once a day (in the AM) on days 1 through 21 of a 28-day cycle for a maxim
Terminated : Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment
: Lymphoma
: 2009-02-25
:
  • Biological: rituximab Given IV
Terminated : Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma
: Lymphoma
: 2003-12-10
:
  • Biological: rituximab
  • Drug: cytarabine
Completed : Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Large Cell Lymphoma
: Lymphoma
: 2000-05-02
:
  • Biological: filgrastim
  • Biological: rituxim
Recruiting : CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273)
: Lymphomas
: 2014-10-22
: Genetic: Anti-CD30 CAR T cells Autologous 4th generation withdrawal lentiviral-transduced anti-CD30 CAR
Completed : Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
: Lymphoma
: 2000-08-03
:
  • Drug: doxorubicin hydrochloride
  • Drug: topo
<<< Previous | Next >>>